Literature DB >> 14975259

MUC1 immunobiology: from discovery to clinical applications.

Anda M Vlad1, Jessica C Kettel, Nehad M Alajez, Casey A Carlos, Olivera J Finn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14975259     DOI： 10.1016/S0065-2776(04)82006-6

Source DB:  PubMed          Journal:  Adv Immunol        ISSN： 0065-2776            Impact factor:   3.543


× No keyword cloud information.
  77 in total

Review 1.  Lung cancer vaccines.

Authors:  Ronan J Kelly; Giuseppe Giaccone
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies.

Authors:  Simone P Pinheiro; Susan E Hankinson; Shelley S Tworoger; Bernard A Rosner; John R McKolanis; Olivera J Finn; Daniel W Cramer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

3.  Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance.

Authors:  Uzoma K Iheagwara; Pamela L Beatty; Phu T Van; Ted M Ross; Jonathan S Minden; Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2013-12-05       Impact factor: 11.151

Review 4.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

Review 5.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.

Authors:  Chuanlin Ding; Li Wang; Jose Marroquin; Jun Yan
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

7.  Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.

Authors:  Juan Carlos Varela; Carl Atkinson; Robert Woolson; Thomas E Keane; Stephen Tomlinson
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

8.  Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis.

Authors:  Deepak K Kadayakkara; Pamela L Beatty; Michael S Turner; Jelena M Janjic; Eric T Ahrens; Olivera J Finn
Journal:  Pancreas       Date:  2010-05       Impact factor: 3.327

9.  Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.

Authors:  Camille Jacqueline; Amanda Lee; Nolan Frey; Jonathan S Minden; Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2020-05-28       Impact factor: 11.151

10.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.